Orthofix Medical Inc. announced the publication of retrospective data evaluating fusion rates in patients receiving three- and four-level lumbar arthrodesis surgery who were treated adjunctively with the SpinalStim™ bone growth therapy device. Following a multicenter retrospective evaluation, data was collected from 55 patients diagnosed with lumbar degenerative disease, spinal stenosis, and/or spondylolistheses who underwent three- or four-level arthrodesis surgery followed by PEMF treatment with the SpinalStim device. At 12-month follow-up, radiographic evaluation of overall fusion rates was 92.7% regardless of patient risk factors. The SpinalStim device is the only bone growth stimulator approved by the U.S. Food and Drug Administration as an adjunct for lumbar spinal fusion procedures and as an option for treating failed spinal fusion surgery. The device emits 360 degrees of PEMF treatment around the fusion site, covering up to five vertebral levels. The SpinalStim system is supported by the STIM onTrack mobile app that enables patients to take an active role in their recovery through daily treatment reminders, usage calendars and the sharing of treatment data with physicians.